Swiss chocolate group Lindt & Sprüngli today (20 August) booked an increase in first-half sales and earnings, boosted by share growth across its “strategically important” markets.

The company said sales in the half to the end of June rose 9.6% to CHF1.13bn. Organic sales, stripping out the impact of currency exchange, were up 8.7%, above consensus expectations of 7.4%. Lindt said revenues were driven by market-beating 12.7% growth in the US, while sales in Europe rose 5.8%.

“Lindt & Sprüngli is developing significantly faster than the overall chocolate market and makes a substantial contribution to its growth,” the company said.

It revealed improved margins meant operating profit gained 42.1% to CHF65.5m in the half, while net profit rose 40.2% to CHF48.8m.

Looking to the full year, Lindt reiterated its sales growth target of 6-8% but added its operating margin improvement would be at the higher end of its 20-40bp target range.

Shares in the firm were up over 2.5% in morning trade today.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Click here for just-food’s two-part interview with Lindt & Sprungli CEO Ernst Tanner, which looks at the company’s performance in developed markets and its patient strategy in emerging economies.